- Home
- HROW vs JANX Comparison
HROW vs JANX Comparison
Compare HROW & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- JANX
- Stock Information
- Founded
- HROW 1998
- JANX 2017
- Country
- HROW United States
- JANX United States
- Employees
- HROW N/A
- JANX N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- HROW Health Care
- JANX Health Care
- Exchange
- HROW Nasdaq
- JANX Nasdaq
- Market Cap
- HROW 1.4B
- JANX 1.4B
- IPO Year
- HROW N/A
- JANX 2021
- Fundamental
- Price
- HROW $39.74
- JANX $24.05
- Analyst Decision
- HROW Strong Buy
- JANX Strong Buy
- Analyst Count
- HROW 7
- JANX 11
- Target Price
- HROW $68.50
- JANX $76.55
- AVG Volume (30 Days)
- HROW 889.7K
- JANX 790.8K
- Earning Date
- HROW 11-12-2025
- JANX 11-05-2025
- Dividend Yield
- HROW N/A
- JANX N/A
- EPS Growth
- HROW N/A
- JANX N/A
- EPS
- HROW N/A
- JANX N/A
- Revenue
- HROW $227,661,000.00
- JANX $439,000.00
- Revenue This Year
- HROW $43.92
- JANX N/A
- Revenue Next Year
- HROW $41.32
- JANX $130.50
- P/E Ratio
- HROW N/A
- JANX N/A
- Revenue Growth
- HROW 47.69
- JANX N/A
- 52 Week Low
- HROW $20.85
- JANX $21.73
- 52 Week High
- HROW $59.23
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- HROW 45.21
- JANX 46.31
- Support Level
- HROW $40.79
- JANX $22.23
- Resistance Level
- HROW $48.79
- JANX $24.57
- Average True Range (ATR)
- HROW 2.41
- JANX 1.20
- MACD
- HROW -0.87
- JANX -0.03
- Stochastic Oscillator
- HROW 11.18
- JANX 31.49
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.